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costs calculation in economic evaluations, measures used to calculate indirect cost, 
and difﬁculties while performing indirect costs estimation. Questionnaires were 
handed out to participants of the 3rd International Symposium Evidence-Based Health 
Care in Cracow, mailed to the Polish Pharmacoeconomic Society members and dis-
tributed directly to experts. RESULTS: Fifty four pharmacoeconomists, health econo-
mists and decision-makers returned completed questionnaires. Mean age of respondents 
33,3 o 7,6 years; mean experience in health economics 4,7 o 5,2 years; 43%(23/54) 
of responders had non-economic background, 41%(22/54) reported government as a 
work environment. All (excluding one) responders indicated that indirect costs should 
be calculated in pharmacoeconomic studies (strongly agree 58%, agree 40%). Experts 
pointed out that indirect cost were calculated in only 24% of reports and represented 
on average 22% of total costs. Twenty three (i.e. 43%) responders indicated human 
capital approach as the best method to estimate cost from societal perspective; friction 
cost method came second best 11%(6/53); 42%(22/53) respondents had no opinion. 
The doers of economics evaluations pointed to GDP per capita (11/18), average salary 
(11/18), and costs of sick pay or injury beneﬁt (11/18) as measures which should be 
used to value production losses. CONCLUSIONS: Indirect costs are considered impor-
tant but seldom executed component of economic evaluations of health care interven-
tions in Poland. The lack of consensus and widely accepted methods for indirect cost 
evaluation support further research.
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OBJECTIVES: Through the increase of economic evaluation studies in Korea, the 
question of transferability from different settings is becoming more and more impor-
tant. However, there are factors that may limit the transferability of study results 
such as variations in the epidemiology, relative pricing and the availability of health 
care resources. Already published by Welte, Boulenger and Urdahl, transferability 
tools are useful and easy to check the transferability among countries. This study 
assessed the transferability with these tools from other settings to Korea settings. 
METHODS: With three selected articles conducted in Belgium, Sweden and USA, 
we evaluated the transferability to Korean settings using 3 methodologies (Welte, 
Boulenger and Urdahl) and then identiﬁed those factors that can be appropriate 
to adapt in Korea settings. RESULTS: In case of Welte, Belgium and US study 
showed low correspondence for disease incidence like 0.4% vs. 0.01% in THR. And 
Sweden study showed different case-mix that the average age of TKR patients were 
higher than THR but Korea case was opposite. According to Boulenger method, the 
scores for Belgim, Sweden and US studies were 51.5, 75 and 75.6 separately. 
Low scores came from the discount and cost mainly due to insufﬁcient description. 
With Urdahl method, three studies well expressed for decision maker, but Belgium 
and Sweden studies did not describe the clinical research enough. The United 
States study explained in detail for the transition probabilities and modeling but the 
unit price and resource use were not related to Korea setting directly due to different 
pricing system. CONCLUSIONS: Through this evaluation, disease incidence, unit 
price and resource use showed low transferability in order to transfer to Korea. We 
could ﬁnd out that data and methods should be presented in a transparent way to 
improve transferability.
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OBJECTIVES: To evaluate an online, freeware, incremental cost-effectiveness calcula-
tor that generates and plots results from a decision tree that utilizes Monte Carlo 
simulations for the variables related to the success probabilities, costs and utilities. 
METHODS: An online cost-effectiveness calculator and plotter were developed that 
incorporates a decision tree structure with Monte Carlo simulations to compare two 
interventions. This decision analysis calculator is available at www.healthstrategy.
com. This online tool uses JavaScript algorithms and was based on an MS Excel model 
description published by Hughes D. His spreadsheet can be downloaded from www.
liv.ac.uk/prg/model.xls. For this evaluation, the spreadsheet structure was modiﬁed 
slightly to match the more basic online tree. Log-normal and beta distributions are 
generated from variable inputs that can be modiﬁed in the web-based software that 
cover costs, utilities and probability of both success and failure for two treatment 
alternatives. RESULTS: The online calculator functions on most computer operating 
systems with JavaScript enabled browsers. The web-based tool creates a scatter plot 
of incremental costs versus incremental utilities in cost-effectiveness quadrants, and 
also graphs a cost-effectiveness acceptability curve. Although the min-max range of 
cost results were similar between the two tools, the range of utility results was greater 
with the web computations. The MS Excel spreadsheet model (1000 simulations) 
versus the online calculator (500 simulations) compared as follows: average incremen-
tal costs ($1919 vs. $1885), average incremental utilities:(0.058 vs. 0.054) and average 
incremental cost effectiveness ratio:($33,086 vs. $34,907). CONCLUSIONS: With 
this online decision tree and Monte Carlo simulator, the user can input their own 
distribution parameters, then generate and graph incremental costs, incremental utili-
ties and cost effectiveness acceptability curves. This web-based calculator has potential 
beneﬁt as a basic educational tool for students and health professionals interested in 
exploring these analytical approaches.
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OBJECTIVES: Since 2005 Austrian regional sickness funds have been facing an 
increase in drug prescription costs of 7–8 % per year. In order to analyze these 
costs we developed a benchmarking system comparing drug prescription costs 
for 2007 of the regional sickness funds including two ratios split into a price and a 
volume component. Calculating the ratios at the high aggregate of the second 
ATC level revealed problems: The total savings potential seemed unrealistically high 
and could not be traced back to a speciﬁc ﬁeld of action. Therefore, the need for a 
re-design of the benchmarking system was more than necessary. METHODS: Since 
the cost-function is interpreted as a function of the distribution of prescriptions, price 
effects can be shown by adjusting the distribution. This is equivalent to shifting pre-
scriptions from speciﬁc drugs to others within a cluster. To legitimize this new method, 
the volume component of each sickness fund is normalized to the average level of 
prescriptions per beneﬁciary (ATC level 2), considering the fund’s distribution of pre-
scriptions in lower ATC levels. The process of clustering starts with substitutable drugs 
according to the national eco-list. After that these clusters are combined to groups at 
ﬁrst ATC level 5 and then ATC level 4. Within these groups the distributions of the 
funds are adjusted to the benchmark’s distribution. RESULTS: In each step of the 
clustering process we used various approaches, like the use of the eco-list or substitu-
tion of drugs by similar agents, to affect the price component. Moreover, the new 
method evaluates the prescription behaviour of contract physicians for each fund. 
CONCLUSIONS: The original method shows that a savings potential cannot be cal-
culated on an aggregate level. The new method provides a more detailed, step-by-step 
analysis and allows to identify—combined with medical quality assurance—possible 
ﬁelds of action.
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OBJECTIVES: Absenteeism costs estimated based on amount of mean sick pay (data 
provided by Social Insurance Institution—ZUS) were calculated for approximately 
a2.3 billion in 2007. The aim of this study was to evaluate the difference between 
absenteeism costs estimated either on mean sick pay or on gross value added in Poland 
in 2007. METHODS: Sickness absence data were derived by ZUS. Alternatively to 
ZUS data, absenteeism cost was estimated based on gross value added and structure 
of employed persons by sectors in sections of national economy derived by Central 
Statistical Ofﬁce (GUS). Based on ZUS and GUS data we calculated value of missed 
day per employed in speciﬁc sector of the economy. The analysis was based on an 
assumption that number of missed days includes only working days (252 days per 
year). Human capital approach was used to estimate the absenteeism costs. Values 
are presented in Euro (exchange rate: 1 Euro  4.50 PLN). RESULTS: Absenteeism 
costs were estimated to amount of a12 billion. Cost of missed days of work due to 
illness per person employed in mining and quarrying (a2062) was more than 5 times 
higher than cost per person employed in education (a380). Mean cost of absenteeism 
was estimated to amount of a1012 per employee. Mean cost of absenteeism estimated 
based on gross value added was more than 6 times higher than those estimated based 
on amount of funds spent on sick pay (a154 per employee). CONCLUSIONS: Given 
that ZUS data on amount of mean sick pay seem to provide reliable absenteeism costs 
in Poland, it would seemed that either data based on wages are underestimated or 
some compensative mechanisms exist in economy that limit indirect cost of sickness 
absence.
PMC22
DEVELOPMENT OF A SENSITIVE RESOURCE USE QUESTIONNAIRE
Daeppen JB1, Kopp P2, Armand C3, Guennec M4, Cochran J3
1CHUV, Lausanne, Switzerland, 2Panthéon-Sorbonne (Paris I) University, Paris, France, 
3Lundbeck SAS, Paris, France, 4Université Victor Segalen (Bordeaux 2), Bordeaux , France
Alcoholism is a chronic disease and the evaluation of its burden usually focuses on 
long-term co-morbidity and mortality. Clinical Trials evaluating new interventions for 
alcohol-dependent patients rarely last more than 12 to 24 months. OBJECTIVES: 
Develop a questionnaire capable of capturing principal resource use yet sensitive 
enough to show short-term economic beneﬁt of drugs developed to reduce consump-
tion in alcohol-dependent patients. METHODS: Comprehensive Medline literature 
search using keywords: Alcohol-related-disorders, economics, cost of illness. Further, 
experts panel discussions provided additional data. RESULTS: Two key cost drivers, 
hospitalisation and sick leaves were identiﬁed by the literature review. Expert ﬁndings 
related to costs of social consequences were incorporated. These three important 
resources were included in the questionnaire in addition to standard medical resource 
use consumption input. Finally, the following items were included: consultation visits, 
hospitalisations, sick leaves and working situation, living situation, social environ-
ment, accidents, arrests and domestic violence. The recall period is 3 months. DISCUS-
SION: A great deal of information is collected in this questionnaire in order to capture 
all relevant resources. Tests to validate the questionnaire in a real-life setting will be 
conducted (face validity, concurrent validity, and test-retest) in a cohort of dependent 
